GlassScriptPhysician profile
Loan Ngoc Vu
NPI 1396799870
$2,717.16
in general payments reported to CMS, 2019-2025
26 companies · $639 in 2025
The $639 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $350 · 2021: $299 · 2022: $439 · 2023: $418 · 2024: $278 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $395.76 | 2022-2025 | |
| Novo Nordisk INC | $371.81 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $227.56 | 2020-2025 | Spravato |
| Gilead Sciences, INC. | $221.20 | 2020-2025 | |
| Lilly USA, LLC | $178.53 | 2020-2025 | Mounjaro |
| Sanofi Pasteur INC. | $158.97 | 2019-2025 | |
| Pfizer INC. | $135.98 | 2020-2025 | |
| Abbvie INC. | $131.28 | 2019-2025 | Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.36 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $95.07 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $93.30 | 2019-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $90.14 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $89.06 | 2021-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $74.44 | 2019-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.88 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $38.30 | 2020 | |
| Phathom Pharmaceuticals, INC. | $36.48 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $34.22 | 2019 | |
| Dexcom, INC. | $34.06 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $28.81 | 2025 | Cologuard Collection Kit |
| Meridian Bioscience INC. | $26.45 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $24.58 | 2022 | |
| Viiv Healthcare Company | $24.57 | 2025 | Apretude |
| Novartis Pharmaceuticals Corporation | $20.44 | 2021 | |
| Eisai INC. | $17.56 | 2020 | |
| Krystal Biotech INC | $15.35 | 2024 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loan Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.